Art. -Nr.: HY-B0312

Dipyridamole

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 58-32-2
Formel: C₂₄H₄₀N₈O₄
Molecular Weight:504.63

Speicherung:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Dipyridamole Chemical Structure

CAS. Nr.: 58-32-2

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

PDE

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
COR-L23	IC₅₀	15 nM Compound: 3, DP	Inhibition of ENT-mediated [3H]thymidine incorporation in human COR-L23 cells by liquid scintillation counting Inhibition of ENT-mediated [3H]thymidine incorporation in human COR-L23 cells by liquid scintillation counting	[PMID: 21366300]
HEK293	IC₅₀	2 μM Compound: Dipyridamole	TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells	[PMID: 12695538]
HEK293	IC₅₀	30 μM Compound: Dipyridamole	TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells	[PMID: 12695538]
K562	IC₅₀	144.8 nM Compound: Dipyridamole	Inhibition of ENT1 in human K562 cells by flow cytometric assay Inhibition of ENT1 in human K562 cells by flow cytometric assay	[PMID: 17636949]
L1210	IC₅₀	0.34 μM Compound: DP	Inhibition of [3H]thymidine uptake in L1210 cells Inhibition of [3H]thymidine uptake in L1210 cells	[PMID: 15369395]
NIH-3T3-G185	IC₅₀	22.7 μM Compound: Dipyridamole	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	23.7 μM Compound: Dipyridamole	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	34.3 μM Compound: Dipyridamole	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
Sf21	IC₅₀	72 μM Compound: 3	Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells	[PMID: 22023548]
U2OS	IC₅₀	8.1 nM Compound: 3108	Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay	[PMID: 31551431]
U2OS	IC₅₀	8.1 nM Compound: 3108	Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861) Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)	[PMID: 31551431]

In Vitro

Dipyridamole (5 μM; 15 min) results in a 2.5-fold increase in intracellular cAMP levels in OCI-AML-3 cells^[2].
Dipyridamole (5 μM; 48 h) with the statin combination induces apoptosis in primary AML cells^[2].
Dipyridamole (5 μM; 48 h) possesse cAMP/PKA-independent activity against statininduced SREBP2 activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

AML (OCI-AML-2, OCI-AML-3) cell line
Concentration:

5 μM
Incubation Time:

48 h
Result:

Induced apoptosis with the combination of fluvastatin and dipyridamole, cilostazol, forskolin, or dbcAMP in OCI-AML-2 and OCI-AML-3 cells.

RT-PCR^[2]

Cell Line:

LP1 cell line
Concentration:

5 μM
Incubation Time:

16 h
Result:

Increased the sensibility of cancer cells to statin-induced apoptosis.

In Vivo

Dipyridamole (10 mg/kg; p.o. once daily for 18 d) mitigates tumor growth, ameliorated concurrent alterations in blood circulation and tumor tissues, and platelet infiltration in tumor tissues^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6-LLC tumor-bearing mice models^[3]
Dosage:

10 mg/kg
Administration:

Oral gavage; 10 mg/kg; once daily for 18 days
Result:

Mitigated tumor growth in tumor-bearing mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 58-32-2
Appearance Solid
Molecular Weight 504.63
Formel C₂₄H₄₀N₈O₄
Color Light yellow to yellow
SMILES

OCCN(CCO)C1=NC(N2CCCCC2)=C(N=C(N(CCO)CCO)N=C3N4CCCCC4)C3=N1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (12)

All Flow CytometryIn Vivo Efficacy StudyHistological Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Cancer

Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth. [Abstract]

2022 Aug;3(8):945-960. PMID: 35982178
Phytomedicine

Mulberroside A inhibits NLRP6 to prevent alveolar macrophage efferocytosis and lung-derived SAA3-platelet transport in high fructose-induced hippocampal inflammation. [Abstract]

2026 Apr:153:157903. PMID: 41655552
Cell Mol Gastroenterol Hepatol

Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis. [Abstract]

2025 May 21:101539. PMID: 40409684

Dipyridamole purchased from MedChemExpress. Usage Cited in: Cell Mol Gastroenterol Hepatol. 2025 May 21:101539. [Abstract]

Representative flow cytometry plots and quantification of the percentage of BNDs and CNBs in naïve B cells treated with Dipyridamole (1 mM; 3 d) or vehicle, in the presence and absence of inosine (250 mM). Dipyridamole nearly reversed the effects of inosine, including the increased frequency of BNDs.

Dipyridamole purchased from MedChemExpress. Usage Cited in: Cell Mol Gastroenterol Hepatol. 2025 May 21:101539. [Abstract]

Mice were injected with ConA (10 mg/kg), inosine (300 mg/kg), or a combination of both, with or without Dipyridamole (1 mg/kg; i.p.; 30 minutes before inosine administration). Representative images of H&E-stained liver sections were obtained. Dipyridamole reversed the substantial reduction in the area of hepatic necrosis in inosine-treated mice.
Invest Ophthalmol Vis Sci

Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity. [Abstract]

2025 Dec 1;66(15):16. PMID: 41334959

Dipyridamole purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2025 Dec 1;66(15):16. [Abstract]

The representative fundus examination images and hematoxylin and eosin-stained images on day 14 after immunization in EAU and preventative Dipyridamole (DIP) (300 mg/kg/day; p.o.; 6 d) groups, with the black arrows indicating inflammatory exudation and linear lesions and the white arrows highlighting retinal folding. Preventative Dipyridamole (DIP) significantly attenuated chorioretinal lesions, infiltrations, and vasculitis.

Dipyridamole purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2025 Dec 1;66(15):16. [Abstract]

The flow cytometry dot plots and column charts showing the percentage of CD4+ cells, CD4+IFN-γ+ and CD4+IL-17A+ cells in the live cells in retinal tissues from the EAU and preventative Dipyridamole (DIP) (300 mg/kg/day; p.o.; 6 d) groups.

Dipyridamole purchased from MedChemExpress. Usage Cited in: Invest Ophthalmol Vis Sci. 2025 Dec 1;66(15):16. [Abstract]

Histograms of the Carboxy fluorescein succinimidyl ester fluorescence intensity and scatter plot showed the proliferation of T cells cultured in different Dipyridamole (DIP) (3-4 μM; 72 h) concentrations. Dipyridamole (DIP) dosedependently suppressed CD4+ T-cell proliferation.
Mediators Inflamm

Sorbitol Destroyed Intestinal Microfold Cells (M Cells) Development through Inhibition of PDE4-Mediated RANKL Expression. [Abstract]

2024 May 2:2024:7524314. PMID: 38725539
Mediators Inflamm

Vitronectin Destroyed Intestinal Epithelial Cell Differentiation through Activation of PDE4-Mediated Ferroptosis in Inflammatory Bowel Disease. [Abstract]

2023 Jul 19:2023:6623329. PMID: 37501933
Res Sq

2026 Jun 15.
bioRxiv

2026 Jan 27.
SSRN

2025 Dec 1.
Chemrxiv

2025 Nov 17.
Research Square Preprint

2024 Apr 9.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (99.08 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9816 mL

9.9082 mL

19.8165 mL

5 mM

0.3963 mL

1.9816 mL

3.9633 mL

10 mM

0.1982 mL

0.9908 mL

1.9816 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Konzentration

Volumen

Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: ≥ 1 mg/mL (1.98 mM); Clear solution

Protocol 5

Add each solvent one by one: 2% DMSO 98% Corn Oil

Solubility: 1 mg/mL (1.98 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kerndt CC, Nagalli S. Dipyridamole. 2021 Nov 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32119342. [Content Brief]

[2]. Longo, Joseph, etal. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Molecular oncology vol. 14,10 (2020): 2533-2545 [Content Brief]

[3]. Wang, Jiaan-Der, etal. Exosomal HMGB1 Promoted Cancer Malignancy. Cancers vol. 13,4 877. 19 Feb. 2021. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9816 mL	9.9082 mL	19.8165 mL	49.5412 mL
	5 mM	0.3963 mL	1.9816 mL	3.9633 mL	9.9082 mL
	10 mM	0.1982 mL	0.9908 mL	1.9816 mL	4.9541 mL
	15 mM	0.1321 mL	0.6605 mL	1.3211 mL	3.3027 mL
	20 mM	0.0991 mL	0.4954 mL	0.9908 mL	2.4771 mL
	25 mM	0.0793 mL	0.3963 mL	0.7927 mL	1.9816 mL
	30 mM	0.0661 mL	0.3303 mL	0.6605 mL	1.6514 mL
	40 mM	0.0495 mL	0.2477 mL	0.4954 mL	1.2385 mL
	50 mM	0.0396 mL	0.1982 mL	0.3963 mL	0.9908 mL
	60 mM	0.0330 mL	0.1651 mL	0.3303 mL	0.8257 mL
	80 mM	0.0248 mL	0.1239 mL	0.2477 mL	0.6193 mL

Keywords

Dipyridamole

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dipyridamole

Apoptosis Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Dipyridamole

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dipyridamole Related Classifications

Art. -Nr.: HY-B0312